Detection method for Her-2 genes of circulating tumor cells in peripheral blood of later-period breast cancer patient

Abstract

The invention discloses a detection method for Her-2 genes of circulating tumor cells in peripheral blood of a later-period breast cancer patient. The detection method comprises the steps that the CTCs in the peripheral blood of the later-period breast cancer patient are separated and acquired through a film filtering device; the circulating tumor cells in the peripheral blood of the later-period breast cancer patient are identified through a cellular immunity fluorescent technique; thin sections are made through a cell wax block technique; the expression condition of the Her-2 of the circulating tumor cells in the peripheral blood of the later-period breast cancer patient is detected through an immunologic tissue chemical technique. According to the detection method, the enrichment CTCs are separated with the help of an ISET technique, the CTCs are identified by depending on the cellular immunity fluorescent technique, and therefore the difficulties existing in CTC identification only through the ISET technique and the false negativity existing in CTC identification only through an immunological detection technique are overcome; meanwhile, the requirement on equipment is not high, the method is easy to master, and real-time monitoring can be achieved. Through the technical method, the expression condition of the Her-2 of the later-period breast cancer patient can be detected without needing to sample the breast cancer tissue.

Description

technical field [0001] The invention relates to a new method for detecting Her-2 gene, in particular to a method for detecting Her-2 gene in patients with advanced breast cancer through peripheral blood. Background technique [0002] Tyrosine kinase-human epidermal growth factor receptor 2 (Her-2, also known as Her2 / neu, c-erbB-2) has gene amplification and protein overexpression in 20%-30% of breast cancer patients . Her-2 positive breast cancer has strong invasiveness, short disease-free survival and poor prognosis. Trastuzumab (Herceptin) is a recombinant DNA-derived humanized monoclonal antibody for Her-2 overexpressing breast cancer. Since only Her-2 overexpressing and gene-amplified breast cancer patients respond to trastuzumab treatment, it is critical to correctly detect and assess the Her-2 status of breast cancer. [0003] There are two commonly used detection methods for Her-2 at present. One is an immunohistochemical method, which determines the Her-2 status ...

AI Technical Summary

Problems solved by technology

[0006] In order to overcome the shortcomings of the traditional circulating tumor cell detection technology and the unsuitable tissue sample collection for patients with advanced breast cancer-thereby failing to evaluate the Her-2 status of patients, the present invention provides a Her-2 gene detection method for circulating tumor cells in peripheral blood of patients with advanced breast cancer. Detection method: use a membrane filtration device to separate and obtain CTCs in the peripheral blood of patients with advanced breast cancer; use cell immunofluorescence technology to identify circulating tumor cells in peripheral blood of patients with advanced breast cancer; use cell wax block technology to make thin-layer sections; and then use immunohistochemical technology Detection of Her-2 expression in peripheral blood circulating tumor cells of patients with advanced breast cancer

Images